Fundamental Data for LMNX

LUMINEX CO(NSDQ:LMNX)

Luminex Corporation has developed, manufactures and markets a proprietarytechnology that simplifies biological testing for the life sciences industry. This industry depends on a broad range of tests, called bioassays, to discover new drugs, identify new genes or simply monitor blood cholesterol levels. The LabMAP system simultaneously performs up to 100 bioassays on a single drop of fluid.

# Employees: 384

Address: 12212 Technology Boulevard,Austin,TX,USA

Phone: 512 219-8020

Fax: 512-219-5195

Website: www.luminexcorp.com

Email: investor@luminexcorp.com

Sector: Medical

Industry: MED INSTRUMENTS

Executive Officers

Patrick J. Balthrop (Presi.; C.E.O.; Dir.)

Harriss T. Currie (V.P.; C.F.O.; Fin.; Treas.)

David S. Reiter (V.P.; Genl. Counsel.; Corp. Sec.)

John C. Carrano Ph.D. (V.P.; Research & Development)

Russell W. Bradley (V.P.; Buss. Devlpt.; Strategic Planning,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/4/2010

Mean EPS (Next Qtr): $0.07

Mean EPS (Year): $0.14

Mean Estimate(Long Term): $33.50

P/E Ratio(Based on EPS estimate): 100.450

Number of Estimates: 14

Shares Performance

Period	LMNX	Compare to S&P
YTD	-34.83 %	-46.06 %
4 Weeks	-12.23 %	-13.18 %
12 Weeks	-9.96 %	-15.11 %

Shares Information

Analyst Coverage: Y

Avg Volume: 473940

Shares Outstanding: 41M

Market Cap: $0.58B

52 Week High: $23.45

52 Week Low: $12.99

P/E Ratio: 126.540

PEG Ratio: 3.000

Split: On 1/1/1990 LMNX split by factor of 0.010

Earnings Performance

EPS Growth in Last Quarter: -133.33 %

EPS Growth in Last Year: -112.50 %

Sales Growth in Last Quarter: 4.74 %

Sales Growth in Last Quarter: 0.76 %

Financials

Qtr Book Value: $2.94

Cash Flow/Share: $57.39

Change in Payout Ratio: 0.000

Price/Sales: 5.220